Docket Number:10A-961030
Inventor:Han-Chung Wu, Chin-Tarng Lin, Lo, Albert
IP Status:TW I372866, US8541543, EP2225262, ZL200880124743.2
Abstract:
Hepatocellular carcinoma is the fifth most common cancer and ranks as the 4th leading cause of cancer death worldwide.
The effect of chemotherapy for the hepatocellular carcinoma remains poor. A novel peptide which binds specifically to hepatocellular carcinoma cells is identified. In vitro, the peptide is shown to bind to hepatocellular carcinoma cell lins. In vivo, the peptide homed specifically to tumor tissue but not to normal visceral organs in hepatocellular carcinoma xenografts.
Fields of Application:
Targeting therapy and drug delivery system of hepatocellular carcinoma
Diagnosis and localize of liver cancer cells
Advantages when compared to the existing technologies:
Lack of tumor specificity remains a major problem for chemotherapies in which side effects prevent the delivery of the drug dosages needed to eliminate the majority of cancer cells.
The targeted drug delivery system enhance the therapeutic efficacy against hepatocellular carcinoma xenografts through enhanced tumor apoptosis and decreased tuomr angiogensis.
Contact Person:
對本技術有興趣,請於本處網頁廠商選項下(廠商需求與諮詢)網頁填寫資料,承辦人將跟您聯絡。
If you are interested in this technology, please fill in the information on the webpage under the manufacturer option (Apply for Technology Licensing, Material Transfer, or Sponsored Research) on the website of this office, and the undertaker will contact you.
